Optimi Health Corp. OPTH
2.38 USD +0.04 (+1.71%)
Nov 9, 2026, 11:01 AM EST
2.15 Day range 2.38
1.90 52-week range 6.40
- YTD
- -60.86%
- 1 year
- -60.86%
- Market cap
- 13.63M
- EPS (ttm)
- -1.56
- YTD return
- -60.86%
- 1-year return
- -60.86%
- Volume
- 13.38K
- Avg volume
- 41.95K
- Open
- 2.19
- Previous close
- 2.34
- Day's range
- 2.15 – 2.38
- 52-week range
- 1.90 – 6.40
5D -0.28 (-10.69%)
Financials — quick view
OPTH Revenue — quarterly 140.20K
OPTH Net income — quarterly -2.40M
OPTH EPS — quarterly -0.56
News
Optimi Health Completes Latest Production Batch Of Its MDMA Finished Drug Product; Proposed Phase 3 Trial Expected To Begin In 2027 
Optimi Health Completes Production Batch Of 5mg Naturally Derived Psilocybin Capsules, Manufactured End To End At cGMP Facility In Princeton, British Columbia 
Elon Musk Once Said Psychedelics Could Help PTSD — Now FDA Holds Hearing as Optimi Health Advances MDMA Trial 
Optimi Health Plans To Initiate A Phase 3 Clinical Trial Evaluating MDMA-Assisted Therapy For PTSD Authorized By Health Canada; Trial Is Expected To Begin In 2027 - Optimi Health Plans To Initiate Multisite Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy For Individuals With Major Depressive Disorder In H1 2027, With Dosing Expected To Be Complete By 2027 End
- Optimi Health Exports Third Shipment Of Its 5Mg Psilocybin Product To Australia Since September 2025
Optimi Health Completes Production Of Two Microdose Psilocybin Finished Drug Products, Formulated At 1 Mg And 2 Mg Dosages; Products Available To Authorized Clinical Research Organizations - Optimi Health Prices Underwritten Public Offering Of 2.40M Common Shares At $6.25/Shr
Your note
Sign in to keep a note on OPTH — it syncs with the Stock Master app.